Evidence map›Paper›PMID 38628785›Full record

ArticleACS medicinal chemistry letters2024

Discovery of α-Amidobenzylboronates as Highly Potent Covalent Inhibitors of Plasma Kallikrein.

Matthew Allison, Rebecca L Davie, Adrian J Mogg, Sally L Hampton, Jonas Emsley, Michael J Stocks

Open access · hybridAbstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Matthew AllisonBiodiscovery Institute, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, United Kingdom.
Rebecca L DavieKalVista Pharmaceuticals Limited, Salisbury, SP4 0BF, United Kingdom.
Adrian J MoggKalVista Pharmaceuticals Limited, Salisbury, SP4 0BF, United Kingdom.
Sally L HamptonKalVista Pharmaceuticals Limited, Salisbury, SP4 0BF, United Kingdom.ORCID https://orcid.org/0000-0002-4305-5461
Jonas EmsleyBiodiscovery Institute, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, United Kingdom.
Michael J StocksBiodiscovery Institute, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, United Kingdom.ORCID https://orcid.org/0000-0003-3046-137X
University of Nottingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hereditary angioedema (HAE), a rare genetic disorder, is associated with uncontrolled plasma kallikrein (PKa) enzyme activity leading to the generation of bradykinin swelling in subcutaneous and submucosal membranes in various locations of the body. Herein, we describe a series of potent α-amidobenzylboronates as potential covalent inhibitors of PKa. These compounds exhibited time-dependent inhibition of PKa (compound

Identifiers

PMID38628785
PMCPMC11017388
OpenAlexW4393277776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.